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OBJECTIVE — The inﬂammation marker YKL-40 is elevated in patients with type 2 diabetes
and is associated with atherosclerosis and increased cardiovascular mortality. In the present
study, YKL-40 levels were examined in patients with type 1 diabetes with increasing levels of
albuminuria, known to be associated with an increased risk of cardiovascular disease.
RESEARCH DESIGN AND METHODS — A total of 149 patients with type 1 diabetes
attending Steno Diabetes Center were examined: 58 had normoalbuminuria (urinary albumin
excretion rate 30 mg/24 h), 46 had persistent microalbuminuria (urinary albumin excretion
rate 30–300 mg/24 h), and 45 had persistent macroalbuminuria/diabetic nephropathy (urinary
albumin excretion rate 300 mg/24 h). The control group consisted of 55 healthy individuals.
Groups were matched according to sex and duration of diabetes (30 years).
RESULTS — Medianlevels[interquartilerange]ofserumYKL-40weresigniﬁcantlyhigherin
normoalbuminuria versus control (37 [29–52] vs. 53 [32–105] ng/ml, P  0.01) and were
increasing with increasing levels of albuminuria (microalbuminuria 74 [45–160] ng/ml and
diabetic nephropathy 117 [68–215] ng/ml; P  0.001 for all comparisons). YKL-40 levels
correlated with the urinary albumin-to-creatinine ratio in the total group of participants (r
2 
0.25,P0.001).SigniﬁcantbutweakintercorrelationsofYKL-40werefoundwithage,diastolic
bloodpressure,A1C,andserumcreatinine.Afteradjustmentforsigniﬁcantcovariates,albumin-
uria was signiﬁcantly associated with YKL-40 levels (P  0.001).
CONCLUSIONS — YKL-40 levels are elevated in patients with type 1 diabetes with an
independent association between increasing YKL-40 levels and increasing levels of albuminuria.
The present study is the ﬁrst to suggest a role of YKL-40 in the gradually progressing vascular
complications in patients with type 1 diabetes.
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ersistent microalbuminuria is an es-
tablished predictor of diabetic ne-
phropathy leading to progressive
renal insufﬁciency and end-stage renal
disease and is associated with an in-
creased risk of cardiovascular disease in
patients with both type 1 and type 2 dia-
betes (1–3). Individuals with diabetes
have, in general, a two- to fourfold in-
creased risk of subsequent cardiovascular
disease (4). A large-scale study of patients
withtype1diabetesdemonstrateduptoa
ninefold increased mortality risk from
ischemic heart disease, which was exces-
sively higher in patients 30 years of age
(5). A substantial proportion of patients
with type 1 diabetes will develop diabetic
nephropathy years after onset of diabetes,
although studies from selected centers
suggest a declining incidence (6,7).
Identiﬁcation of predictors of cardio-
vascular disease and progression of ne-
phropathyinpatientswithtype1diabetes
is important. The fact that the urinary
albumin excretion rate is associated
with an increased risk of cardiovascular
morbidity and mortality (2), even in
nondiabetic individuals and also at lev-
els below the threshold of microalbu-
minuria (low-grade albuminuria) (8),
suggests that an increasing urinary al-
bumin excretion rate reﬂects vascular
damage in the kidneys as part of sys-
temic endothelial dysfunction (9). En-
dothelial dysfunction is the initial step
in atherogenesis, which is largely re-
sponsible for the development of isch-
emic heart disease and thrombotic
strokes (10).
YKL-40 is a marker of inﬂammation
and endothelial dysfunction. It is a
growth factor for several cell types and
has an established role in extracellular
matrixremodelingandangiogenesis(11).
A substantial body of evidence indicates
thatYKL-40participatesinprocessesdur-
ing the early stages of atherosclerosis, and
itseemstobeofpathogenicimportancein
thelow-gradeinﬂammationthatprecedes
the development of cardiovascular dis-
ease (11–14). We have previously found
signiﬁcantly elevated levels of YKL-40 in
patients with type 2 diabetes and an inde-
pendent positive correlation with insulin
resistanceandparametersofthelipidpro-
ﬁle (15,16).
Studies of YKL-40 have never been
performed in patients with type 1 diabe-
tes.Theobjectiveofthepresentstudywas
to evaluate serum YKL-40 levels in pa-
tients with type 1 diabetes and with in-
creasing levels of albuminuria. On the
basis of previous studies, we expected
to ﬁnd 1) higher serum YKL-40 levels in
patients with type 1 diabetes and 2) in-
creasing serum YKL-40 levels with in-
creasing levels of albuminuria explained
by a progressive systemic endothelial
dysfunction.
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METHODS— The present study was
basedondatausedtoidentifybiomarkers
of diabetes and diabetic nephropathy by
proteomic analyses. The participants
wereexaminedattheStenoDiabetesCen-
terin2004andconsistedof55Caucasian
healthyindividuals(controlsubjects)and
three groups of Caucasian patients with
type 1 diabetes attending the Steno Dia-
betes Center. On the basis of 24-h urine
collections analyzed as part of the routine
care of the patients before the present
study, they were divided into 58 patients
with normoalbuminuria (urinary albu-
min excretion rate 30 mg/24 h), 46 pa-
tients with persistent microalbuminuria
(at least two of three consecutive urine
samples with albumin excretion rate 30–
300 mg/24 h), and 45 patients with per-
sistent macroalbuminuria/diabetic
nephropathy (albumin excretion rate
300 mg/24 h). Groups were matched at
the group level by sex, age (5 years),
anddurationofdiabetes(3years)(20
years, for normoalbuminuric patients).
Control subjects were randomly selected
from the general healthy population by
advertisement in the local news. They
were enrolled in the study if they had
plasma glucose levels 6 mmol/l after an
overnight fast and had no prior history of
cardiovascular disease including hyper-
tension. Subjects referred to the hospital
on the suspicion of diabetes or other en-
docrine diseases were not included even
though a diagnosis was not conﬁrmed.
Matchingofcontrolsubjectswithindivid-
uals from all the diabetic groups at indi-
vidual level was not possible.
Investigations were performed in the
morning after an overnight fast. Arterial
blood pressure was measured three times
with an appropriate-sized cuff after at
least 10 min supine rest. Urinary albumin
concentration was measured by an en-
zyme immunoassay from early morning
spot urine collections. Serum and urine
creatinine concentration was assessed by
a kinetic Jaffe ´ method. Plasma samples
were stored at 80°C until analysis. Glo-
merular ﬁltration rate (GFR) was esti-
mated using the four variable
ModiﬁcationofDietinRenalDiseaseGFR
formulas (age, sex, race, and serum creat-
inine) (http://mdrd.com). Diabetic reti-
nopathy was assessed in all patients by
fundus photography after pupillary dila-
tation and graded as nil, simplex, or pro-
liferative. Patients were interviewed using
the World Health Organization cardio-
vascularquestionnaire.Smokerswerede-
ﬁnedasindividualssmokingcigarettes/
cigars/pipes a day; all others were clas-
siﬁed as nonsmokers.
The study was approved by the local
ethics committee. All patients gave their
informed consent.
Serum YKL-40 was analyzed with a
commercialassay(ELISA;Quidel,SanDi-
ego, CA) on material frozen at the time of
inclusion. The measuring range of the as-
say was 20–300 ng/ml, and the intra-
assay and interassay coefﬁcients of
variationwere5.8and6.0%,respectively.
Statistical analysis
Comparisons between the groups were
made with the Kruskal-Wallis test for or-
dinal data. Continuous data were com-
paredwithone-wayANOVA.Ifdatahada
non-Gaussian distribution as seen in a P
plot, data were logarithmically trans-
formed. Analyses of intercorrelations and
Table 1—Clinical data of the control group and the diabetic patients differentiated according to level of albuminuria
Control
group Normoalbuminuria Microalbuminuria Macroalbuminuria P
n, total 55 58 45 46 0.46
Male sex (%) 65.4 51.7 53.3 58.7 0.0001
Age (years) 50.5  10.9 55.6  10.8 54  11.1 49  9.6 0.005
Diabetes duration (years) 36.8  10.5 35.5  11.3 33.9  10.5 0.39
BMI (kg/m
2) 25.8  3.6 24.7  2.9 25.1  3.7 25.1  4.3 0.46
Smoking 10 (18.2) 12 (20.7) 13 (28.9) 19 (41.3) 0.09
Use of antihypertensive medications 0 28 (48.3) 43 (95.6) 43 (93.5) 0.0001
Use of statins 2 (3.6) 16 (27.6) 18 (40) 23 (50) 0.0001
Use of aspirin 2 (3.6) 21 (36.2) 27 (60) 29 (63) 0.0001
YKL-40 (ng/ml) 37 (27–52) 53 (32–105) 74 (45–160) 117 (68–215) 0.0001
A1C (%) 5.5  0.3 8.2  1.1 8.8  1.3 8.8  1.1 0.0001
Creatinine (mol/l) 95 (87–104) 92 (83–97) 89 (81–101) 125 (100–174) 0.0001
UACR (mg/g) 5 (3–8) 5 (4–8) 26 (11–63) 500 (208–1,155) 0.0001
eGFR (ml/min per 1.73 m
2) 70.5  9.6 70.3  10.3 70.7  13.4 49.2  19.2 0.0001
Cholesterol (mmol/l) 5.5  0.9 4.8  0.8 5.0  1.0 4.9  1.0 0.0001
Systolic blood pressure (mmHg) 132  16 138  21 141  23 140  24 0.94
Diastolic blood pressure (mmHg) 81  10 74  11 74  12 76  12 0.003
History of
Myocardial infarction 0 3 (5) 5 (11.1) 3 (6.5) 0.11
Stroke 0 4 (6.9) 4 (8.9) 4 (8.7) 0.17
Intermittent claudication 0 4 (6.9) 8 (17.8) 8 (17.4) 0.005
Retinopathy
None — 6 (10.3) 1 (2.2) 2 (4.4) 0.0001
Simplex — 19 (32.8) 11 (24.4) 10 (21.7) 0.0001
Proliferative — 33 (56.9) 33 (73.3) 34 (73.9) 0.0001
Data are mean  SD, median (interquartile range), or number (%) unless speciﬁed otherwise. *Some patients had UACR levels reduced by antihypertensive
medication, which was not stopped when spot urine samples were collected for the study.
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variate linear regression analysis.
P values were two-sided, and P 
0.05 was considered statistically signiﬁ-
cant. All analyses were made with the sta-
tistical software package SPSS (version
11.5; SPSS, Chicago, IL).
RESULTS— Clinical data for the con-
trolgroupandthediabeticpatientsdiffer-
entiatedaccordingtolevelofalbuminuria
are shown in Table 1. YKL-40 levels ac-
cording to level of albuminuria are illus-
trated in Fig. 1. The groups were well
matched regarding sex and duration of
diabetes, but the age-match was ruined
becauseofafewpatientswithmissingval-
ues and because of exclusion of a patient
with nondiabetic nephropathy from the
macroalbuminuria group.
Median YKL-40 levels were signiﬁ-
cantly different among all groups with in-
creasing YKL-40 levels with increasing
levels of albuminuria (P  0.001). As
expected, we found signiﬁcantly lower
estimated GFR (eGFR) in the mac-
roalbuminuria group (P  0.0001) but
equivalent eGFR in the control, nor-
moalbuminuria, and microalbuminuria
groups. We found no signiﬁcant differ-
ence in systolic blood pressure between
thegroupsforallcomparisonsorforcom-
parisons of the diabetic groups, but there
was a signiﬁcant difference between the
control subjects and the macroalbumin-
uria group (P  0.041) and the control
subjects and the microalbuminuria group
(P0.028).Thesigniﬁcantdifferencesin
diastolic blood pressure and serum cho-
lesterol for all comparisons were due to
differences between control subjects and
thediabeticgroupsintotal.Nosigniﬁcant
differences in diastolic blood pressure or
serum cholesterol were found between
the diabetic groups (P  0.68 and P 
0.39, respectively). There was a signiﬁ-
cant difference in use of antihypertensive
drugs between the groups (P  0.0001).
Almost half of the normoalbuminuric
group (48.3%) and close to all subjects in
the microalbuminuria (95.6%) and mac-
roalbuminuria (93.5%) groups were us-
ing antihypertensive specimens.
Although we found a signiﬁcant dif-
ference in A1C for all comparisons, no
signiﬁcant difference was found between
the micro- and macroalbuminuria groups
(P  0.94).
Multiple regression analyses showed
correlation of YKL-40 with the urinary al-
bumin-to-creatinine ratio (UACR) in the
total group of participants (r  0.50, P 
0.001)(Table2).Thiscorrelationwasnot
signiﬁcant in any of the different sub-
groups. Signiﬁcant intercorrelations of
YKL-40werealsofoundwithA1C,serum
creatinine, age, and diastolic blood pres-
sure, respectively, in the total group of
participants (Table 2). No signiﬁcant cor-
relation was found between YKL-40 and
systolicbloodpressure,BMI,ortotalcho-
lesterol, and YKL-40 levels were not pre-
dicted by GFR (P  0.73).
Inamultipleregressionmodeladjust-
ing for the signiﬁcant covariates (UACR,
A1C, serum creatinine, age, and diastolic
blood pressure) and cholesterol, systolic
blood pressure, and the presence of inter-
mittent claudication and retinopathy,
YKL-40 levels were signiﬁcantly associ-
ated with the level of albuminuria (P 
0.001). Pairwise comparisons between
the groups showed a signiﬁcant associa-
tion between YKL-40 levels and increas-
ing levels of albuminuria to the level of
microalbuminuria (Table 3). No signiﬁ-
cant difference in this association was
found between the micro- and mac-
roalbuminuria groups (P  0.08).
At baseline, only a limited number of
patients had symptoms of intermittent
claudicationorpreviousepisodesofmyo-
cardial infarction or stroke (Table 1). Pa-
tients with intermittent claudication and
stroke had signiﬁcantly higher YKL-40
levels than individuals without these ma-
crovascular complications (P  0.021
and P  0.05, respectively), but in accor-
dance with the multiple regression analy-
ses adjusting for the presence of
retinopathy and intermittent claudica-
tion, these associations became insigniﬁ-
cant with adjustment for the signiﬁcant
covariates.
CONCLUSIONS — The micro- and
macrovascular complications of diabetes
remain a constant challenge to quality of
life as well as to life expectancy. Intensive
Figure 1—Median levels (interquartile range) of YKL-40 in the three diabetic groups compared
with the control group: 37 (29–52) ng/ml in the control group, 53 (32–105) ng/ml in the patients
with normoalbuminuria, 74 (45–160) ng/ml in patients with microalbuminuria, and 117 (68–
215) ng/ml in patients with macroalbuminuria/diabetic nephropathy (P  0.0001).
Table 2—Intercorrelations of YKL-40
Correlation
coefﬁcient P
UACR 0.50 0.0001
A1C 0.36 0.001
Creatinine 0.33 0.001
Age 0.16 0.025
Diastolic blood
pressure 0.14 0.049
Log-transformed data. Multiple regression analyses
adjusted for sex, BMI, creatinine, cholesterol, and
systolic blood pressure.
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thepathogenesisandaboutseveralpoten-
tially modiﬁable risk factors, including
poor glycemic control, increased urinary
albumin excretion, hypertension, and
smoking. Despite improved and intensi-
ﬁed treatment of diabetes and its vascular
risk factors and complications, supple-
mentary risk markers alone or in combi-
nation addressing other and earlier
aspects of the pathogenesis are needed.
Fortheﬁrsttime,YKL-40,amarkerof
inﬂammation and endothelial dysfunc-
tion, has been evaluated in patients with
type 1 diabetes. We found elevated
YKL-40 levels in patients with type 1 dia-
betescomparedwithcontrolsubjectsand
showed increasing YKL-40 levels with in-
creasing levels of albuminuria. This ﬁnd-
ing is in accordance with previous studies
showing that chronic low-grade inﬂam-
mation is associated with the occurrence
and progression of (micro)albuminuria
(17)andthatbothmicro-andmacroalbu-
minuria are accompanied by increased
levels of a variety of markers of endothe-
lial dysfunction (18). Several studies have
shown that biomarkers of endothelial
dysfunction and inﬂammation are ele-
vated in patients with type 1 diabetes
without as well as with microvascular
complications or diabetic nephropathy
(18–20).Somestudiesalsoshowanasso-
ciationwithadeclineinGFR(20),cardio-
vascular morbidity (19,20), and overall
mortality (20). Chronic low-grade in-
ﬂammation and endothelial dysfunction
seem to be closely linked, and it seems
that chronic low-grade inﬂammation can
be both a cause and a consequence of en-
dothelial dysfunction (18). It seems
likely, therefore, that the high risk of car-
diovasculardiseaseinpatientswithtype1
diabetes could partly be described by in-
creased inﬂammatory activity initiated by
endothelial dysfunction and that an in-
ﬂammatorystateshouldbeaddressedasa
risk factor in its own.
Dysfunction of the vascular endothe-
lium is considered an important factor in
the pathogenesis of diabetic micro- and
macroangiopathy (18). Studies show that
YKL-40 plays a role in endothelial dys-
function in relation to cell migration, re-
organization, and tissue remodeling
during atherogenesis (12–14). YKL-40
promotes chemotaxis, cell attachment,
spreading, and migration of vascular en-
dothelial cells, suggesting that YKL-40
promotes the process of atherosclerotic
plaque formation, in which vascular
smooth muscle cells (VSMCs) are in-
duced to migrate through the intima in
response to exogenous signals (13).
YKL-40alsomodulatesvascularendothe-
lialcellmorphologybypromotingthefor-
mation of branching tubules, indicating a
role of YKL-40 in angiogenesis by stimu-
latingthemigrationandreorganizationof
VSMCs (13). Furthermore, YKL-40 is
produced and secreted by monocytes
during differentiation to macrophages
but is also secreted by activated macro-
phages (11), and YKL-40 protein expres-
sionisfoundinvivoinbothmacrophages
and VSMCs in the atherosclerotic plaque
(11).Inaccordancewiththisﬁnding,nor-
moalbuminuric type 1 diabetic patients
havebeenfoundtohaveincreasedmono-
cytic activity characterized by increased
monocytic release of interleukin-6 and
superoxideanion,whichisaccentuatedin
type 1 diabetic patients with microvascu-
lar complications (21). Therefore, sub-
stantial evidence indicates that YKL-40
participates in monocyte differentiation
and macrophage activation as part of the
endothelialdysfunctionandtheprocesses
during early stages of atherosclerosis (11)
andseemstobeofpathogenicimportance
in the low-grade inﬂammation that pre-
cedes the development of cardiovascular
disease. We have previously found ele-
vated YKL-40 levels in patients with type
2 diabetes (15,16) in whom it correlated
with insulin resistance and parameters of
the lipid proﬁle, but despite a known
macrophage inﬁltration in adipose tissue,
YKL-40 has never been found to be asso-
ciated with BMI (15).
Because YKL-40 is excreted by the
kidneys,we,notsurprisingly,foundasig-
niﬁcant correlation between YKL-40 and
UACR,butwedidnotﬁndthatincreasing
YKL-40levelswerepredictedbyadecline
in eGFR. Despite the correlation between
YKL-40andUACR,wefoundasigniﬁcant
association between YKL-40 levels and
level of albuminuria after adjustment for
signiﬁcant covariates, implicating in-
creasing albuminuria with increasing
YKL-40 levels. Patients with micro- and
macroalbuminuriaalsohadahigherprev-
alence of retinopathy and intermittent
claudication, but adjustment for these
complications did not attenuate the asso-
ciationbetweenYKL-40levelsandlevelof
albuminuria. The insigniﬁcant associa-
tion when the macroalbuminuria level
was reached is most likely explained by a
systemically accentuated inﬂammatory
state marginalizing the individual impact
of YKL-40. This is in accordance with the
ﬁnding of a larger proportion of individ-
ualswithproliferativeretinopathyandin-
termittent claudication in the micro- and
macroalbuminuria group and with the
perception of YKL-40 as an early marker.
We have previously shown an association
betweenYKL-40andanincreasedcardio-
vascular mortality rate in an elderly part
of the general population without known
diabetes and cardiovascular disease after
adjustmentforknowncardiovascularrisk
factors and markers (16). In the same
study, YKL-40 and UACR were indepen-
dent markers of cardiovascular mortality
withonlyweakintercorrelationandinac-
cordance with the studies on low-grade
albuminuria and risk of cardiovascular
disease, YKL-40 and low-grade albumin-
uria synergistically predicted cardiovas-
cular mortality. Other studies support
this association between YKL-40 and car-
diovascular morbidity and mortality, be-
cause YKL-40 levels are found to be
associatedwiththepresenceandextentof
coronaryarterydiseaseasassessedbycor-
onary angiography (22), and, just re-
cently, YKL-40 levels have been found to
be elevated in patients with myocardial
infarction (23).
Several studies have investigated the
role of YKL-40 in relation to cancer, but
Table 3—Associations between YKL-40 and levels of albuminuria
Pairwise comparisons of levels of albuminuria
Mean difference
of YKL-40 P
Macroalbuminuria Microalbuminuria 1.38 (0.96–1.98) 0.08
Normoalbuminuria 2.02 (1.41–2.90) 0.0001
Control subjects 4.31 (2.48–7.46) 0.0001
Microalbuminuria Normoalbuminuria 1.46 (1.09–1.96) 0.012
Control subjects 3.13 (1.85–5.28) 0.001
Normoalbuminuria Control subjects 2.13 (1.35–3.38) 0.001
Data are ng/ml (95% CI). Multiple regression analysis after adjustment for UACR, age, A1C, creatinine,
cholesterol, systolic and diastolic blood pressure, and the presence of retinopathy and intermittent claudi-
cation.
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role of YKL-40 in cancer, newer results
are conﬂicting (24,25). YKL-40 levels are
particularly high in recurrent cancer
states and highly differentiated cancers,
which are characterized by high vascular-
ization and a high turnover of extracellu-
lar matrix (24). One could hypothesize
that YKL-40 may play a role in cancer be-
cause of its general role in extracellular
tissue remodeling and its inﬂuence on
proliferation and differentiation of vascu-
lar smooth muscle cells and vascular en-
dothelial cells, but in vivo proof of this
hypothesis is yet to be obtained. In our
previous study, in which we found
YKL-40tobeanindependentpredictorof
overall and cardiovascular mortality, we
did not ﬁnd higher YKL-40 levels in indi-
viduals dying of cancer (16).
Limitations of the present study are
the lack of investigation of other markers
of endothelial dysfunction and inﬂamma-
tion, in particular, high-sensitivity C-re-
active protein (hsCRP) because of a
limited amount of biological material.
However,previousstudieseitherhavenot
shown or have shown only a weak corre-
lation between YKL-40 and hsCRP (r 
0.17, NS, and r  0.22, P  0.0001, re-
spectively) (15,16), and hsCRP levels
have not previously been found to inﬂu-
ence the predictive value of YKL-40 in
terms of overall or cardiovascular mortal-
ity (16). Therefore, we would not expect
different outcomes if we included hsCRP
in the analyses.
The perception of YKL-40 as an early
marker (16) indicates that YKL-40 could
possibly correlate with other early mark-
ers of endothelial activation and/or dys-
function.Wefoundatrendtowardhigher
YKL-40 levels in individuals with macro-
vascular complications, but because of a
limited number of cases, the association
was not statistically signiﬁcant. The pre-
dictive value of YKL-40 with regard to al-
buminuria and the progression to
nephropathy as well as the development
of macrovascular complications and car-
diovascular mortality is properly investi-
gated in a prospective study, which is our
next approach.
In summary, YKL-40 levels are ele-
vated in patients with type 1 diabetes and
increase with levels of albuminuria.
YKL-40 levels are independently associ-
ated with increasing levels of albumin-
uria to the level of microalbuminuria
after adjustment for UACR, age and
other signiﬁcant covariates, and the
presence of retinopathy and intermit-
tent claudication.
Taken together, these results suggest
a role for YKL-40 in the gradually pro-
gressing vascular complications in pa-
tients with diabetes, with YKL-40 being a
possible early marker of microvascular
complications. Further studies to impli-
cate other inﬂammation markers and car-
diovascular follow-up are needed.
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